Endpoint News: A Swedish biotech is targeting thrombosis using the body’s own defense system to prevent blood clots with lower risk of bleeding associated with current antithrombotic therapies

2 oktober, 2018

Every two seconds a person is affected by thrombosis. Blood clots forming and blocking the circulation in veins and arteries is the number one cause of death globally, with complications such as myocardial infarction and stroke accounting for the majority of fatalities. Patients at risk of developing blood clots receive preventive treatment with antithrombotic agents often called blood-thinning medicines such as Warfarin, aspirin and the later introduced NOACs. These drugs have been the standard of care for decades, but they all come with a high price to pay: the risk of uncontrolled bleeding.

Read the article